Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction ...

Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments.